VKTX files 8-K with Q3 2025 results and corporate update

Rhea-AI Filing Summary

Viking Therapeutics (VKTX) furnished an 8-K announcing it issued a press release reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1. The company notes that the information under Item 2.02 is furnished, not filed, under the Exchange Act.

false000160767800016076782025-10-222025-10-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2025

Viking Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37355	46-1073877
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
9920 Pacific Heights Blvd, Suite 350
San Diego, California				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 704-4660

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		VKTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 22, 2025, we issued a press release reporting our financial results for the third quarter ended September 30, 2025 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No		Description
99.1		Press release issued October 22, 2025, reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Viking Therapeutics, Inc.
Date:	October 22, 2025	By:	/s/ Brian Lian, Ph.D.
			Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did VKTX announce in this 8-K?

The company furnished a press release reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update.

Which 8-K item applies to Viking Therapeutics (VKTX)?

Item 2.02, Results of Operations and Financial Condition.

What period does the press release cover for VKTX?

The third quarter ended September 30, 2025.

Which exhibits are included in the filing?

Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File).

Is the information considered furnished or filed?

It is furnished under Item 2.02 and is not deemed filed under the Exchange Act.

Who signed the 8-K for VKTX and when?

Brian Lian, Ph.D., President and CEO, signed on October 22, 2025.